A Phase 3, Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks in Direct-Acting Antiviral-Experienced Subjects with Chronic HCV Infection (POLARIS 1: GS-US-367- 1171)
||Male and Female Patients
|U.S. Govt. ID:
||Theresa Lukose: 212-305-6758 / email@example.com
The purpose of this study is to evaluate the efficacy, safety, and tolerability of SOF/VEL/GS- 9857 FDC in patients infected with Hepatitis C (HCV), and previously treated unsuccessfully. Information about any side effects that may occur will also be collected.
This study is closed
Elizabeth Verna, MD
|Have you been diagnosed with Chronic HCV Infection?